Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | PSMAddition: 177Lu-PSMA-617 plus SOC vs. SOC alone in metastatic hormone-sensitive prostate cancer

Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medicine, New York City, NY, provides an overview of an ongoing Phase III study named PSMAddition (NCT04720157) which aims to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus standard of care alone in patients with metastatic hormone-sensitive prostate cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Dr Tagawa reports research support (to Weill Cornell since 2007) for Sanofi, Medivation, Astellas, Janssen, Amgen, Progenics, Dendreon, Lilly, Genentech, Newlink, BMS, Inovio, AstraZeneca, Immunomedics, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, Abbvie, Karyopharm, Endocyte, Clovis, Seattle Genetics, Novartis, Gilead, POINT Biopharma.

Dr Tagawa reports paid consultancy (since 2007) for Sanofi, Medivation/Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis, Clarity, Genomic Health, POINT Biopharma, Blue Earth Diagnostics, AIkido Pharma, Telix Pharma, Convergent Therapeutics.

Dr Tagawa reports unpaid consultancy for Atlab Pharma, Phosplatin Therapeutics, Amgen, Ambrx